SK&F S-106203

peptidoleukotriene receptor antagonist

Also Known As:

3-(2-carboxyethylthio)-3-(2-(8-phenyloctyl)phenyl)propanoic acid; SK&F 106203; SK&F-S-106203; SK&F-S106203; SKF 106203; SKF S106203; SKF-106203

Networked: 1 relevant articles (0 outcomes, 1 trials/studies)

1.	Bronchial Spasm 01/01/1991 - "The AUC obtained for SK&F S-106203 following i.v. administration was 87.3 +/- 7.5 micrograms-h/ml. Following an oral dose of SK&F S-106203 (100 mg/kg), the maximal plasma concentration (Cmax) and the time Cmax was achieved (Tmax) were 21.62 +/- 2.26 micrograms/ml and 4 +/- 1 h, respectively; the AUC was 279.9 +/- 41.8 micrograms-h/ml. Studies examining the effects of i.v. infusion of SK&F S-106203 revealed that marked inhibition of LTD4-induced bronchospasm was produced with steady-state plasma levels of SK&F S-106203 less than 1 microgram/ml (less than 2 microM). " 01/01/1991 - "Oral (p.o.) pretreatment with 100 mumol/kg SK&F S-106203 for up to 24 h essentially abolished LTD4-induced bronchospasm; this correlated with sustained plasma concentrations of greater than 2 micrograms/ml. The results indicate that in guinea-pig airways, SK&F S-106203 is a potent and selective LT receptor antagonist that is active via aerosol, oral and i.v. routes of administration. "
2.	Asthma (Bronchial Asthma) 01/01/1991 - "SK&F S-106203 may be useful therapy in asthma and other disorders in which the LTs are thought to play a prominent pathophysiological role."

1.	Aerosols

1.	Therapeutics